title: Genome-Driven Paradigm for the Development of Selective Fibroblast Growth Factor Receptor Inhibitors.
authors.affiliation: Alison M. Schram, Memorial Sloan Kettering Cancer Center; and Martin H. Voss and David M. Hyman, Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College, New York, NY.
authors.forename: Alison M
authors.initials: AM
authors.lastname: Schram
authors.affiliation: Alison M. Schram, Memorial Sloan Kettering Cancer Center; and Martin H. Voss and David M. Hyman, Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College, New York, NY.
authors.forename: Martin H
authors.initials: MH
authors.lastname: Voss
authors.affiliation: Alison M. Schram, Memorial Sloan Kettering Cancer Center; and Martin H. Voss and David M. Hyman, Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College, New York, NY.
authors.forename: David M
authors.initials: DM
authors.lastname: Hyman
mesh_terms: D006801:Humans; D009369:Neoplasms; D010671:Phenylurea Compounds; D011743:Pyrimidines; D051496:Receptor, Fibroblast Growth Factor, Type 1; D017468:Receptors, Fibroblast Growth Factor
chemical_list: D010671:Phenylurea Compounds; D011743:Pyrimidines; D017468:Receptors, Fibroblast Growth Factor; C568950:infigratinib; D051496:Receptor, Fibroblast Growth Factor, Type 1